Clinical trials: Carcinoma, Breast
Breast Cancer
Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant, anastrozole, or exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount…
- Trial name
- SoFEA (NCT00253422)
- Testing
- Anastrozole, Exemestane, Fulvestrant
- Where
- 2 sites in United Kingdom
- Volunteers
- 698 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Breast Cancer
Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve
This is a multicentre, prospective study willing to evaluate AMH levels changes in response to chemotherapy plus GnRHa. In the present study we propose to determine AMH levels in breast cancer patients, aged <40yrs receiving…
- Trial name
- NCT02113553
- Testing
- Triptorelin
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Armando Santoro, MD
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.
- Trial name
- NCT06846437
- Testing
- JSKN003, Trastuzumab emtansine (T-DM1)
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Shanghai JMT-Bio Inc.
Breast Cancer, Lung Cancer
Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer
This is a multicenter, open-label, randomized, controlled study to test the hypothesis that ePRO monitoring added to usual care helps prolong OS or maintain and improve HRQoL in patients with unresectable advanced cancers or…
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer
- Trial name
- NCT05931445
- Testing
- e-PRO monitoring
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Comprehensive Support Project for Oncology Research
Breast Cancer
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
The purpose of this study is to test the safety of a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast cancer.
- Trial name
- NCT03542175
- Testing
- Rucaparib, Radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
The aim of this project is to evaluate whether the sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by…
- Trial name
- NCT06975475
- Testing
- SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Breast Neoplasms
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.
- Trial name
- NCT00078000
- Testing
- SU011248
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Pfizer
Breast Cancer
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
This is an open-label, single arm, single center, non-randomized feasibility study of the Muse MRgFUS System in subjects with breast cancer.
- Trial name
- BreastMRgFUS (NCT05291507)
- Testing
- Muse MRgFUS System
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Utah
Breast Cancer
Facilitating Positive Adaptation to Breast Cancer
The purpose of this study is to test the effects of a 10-wk cognitive behavioral stress management (CBSM) intervention vs. a single-day psycho-educational seminar on psychosocial adaptation and physiological adaptation in women…
- Trial name
- NCT01422551
- Testing
- Cognitive Behavioral Stress Management, a psycho-educational control
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- University of Miami
Breast Cancer
Identification and Semi -Quantification of ER/PR Proteins Expression
The purpose of the study is the identification and quantification of proteins expression level in breast cancer tissues. The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting…
- Trial name
- NCT02654431
- Testing
- Breast Cancer patient, Cancer patients
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Applied Spectral Imaging Ltd.
Breast Cancer
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
This randomized phase II trial is studying metronomic low-dose cyclophosphamide and methotrexate to see how well they work compared to metronomic low-dose cyclophosphamide, methotrexate, and bevacizumab in treating women with…
- Trial name
- NCT00083031
- Testing
- bevacizumab, cyclophosphamide, methotrexate
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasm
Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12
The primary objectives of the study are to evaluate the feasibility and toxicity of treatment with 12 weeks of Adriamycin with daily oral Cytoxan with G-CSF support followed by 12 weeks of Taxol.
- Trial name
- NCT00194753
- Testing
- Paclitaxel, Doxorubicin, Cyclophosphamide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Washington
Metastatic Breast Cancer, Triple Negative Breast Cancer
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
Primary objective: To provide preliminary evidence on the efficacy of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic triple-negative PD-L1 positive breast cancer patients as evaluated by %…
- Conditions
- Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation
- Trial name
- NCT05266937
- Testing
- Atezolizumab,Paclitaxel, Carboplatin
- Where
- 15 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Consorzio Oncotech
Erector Spinae Plane Block, Serratus Posterior Superior Intercostal Plane Block
Comparison of Erector Spinae Plane Block and Serratus Posterior Superior Intercostal Plane Block
Breast cancer is the most common malignancy in women. Modified radical mastectomy, a surgical procedure in the treatment of breast cancer, is one of the standard treatments.
- Conditions
- Erector Spinae Plane Block, Serratus Posterior Superior Intercostal Plane Block, Acute Pain, Postoperative Pain
- Trial name
- NCT06407037
- Testing
- Erector Spinae Plane Block, Serratus Posterior Superior Intercostal Plane Block
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Diskapi Yildirim Beyazit Education and Research Hospital
Early-Stage Breast Cancer
Proton Therapy for Early Stage Breast Cancer
The purpose of this study is to determine if partial breast proton therapy is effective treatment for early stage breast cancer following lumpectomy.
- Trial name
- NCT00614172
- Testing
- Proton radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Loma Linda University
Breast Cancer
Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
- Trial name
- NCT00285857
- Testing
- Lovastatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Breast Carcinoma
Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients
This clinical trial investigates the effect and tolerability of cryotherapy and to evaluate whether they can prevent or improve taxane-induced sensory peripheral neuropathy in breast cancer patients.
- Trial name
- NCT04256512
- Testing
- Medical Device Usage and Evaluation, Questionnaire Administration
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Breast Cancer
Determination of Autonomic Responses to Exposure to Electromagnetic Fields With Low Energy Modulated Frequency
This is an exploratory study, national, unicentric, double-blind, to be conducted at the Institute for Teaching and Research of the Hospital Sírio-Libanês in order to detect possible autonomic responses resulting from Exposure to…
- Trial name
- NCT01686412
- Testing
- Electromagnetic Fields of Low Energy (EEFLE)
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospital Sirio-Libanes
Breast Cancer
A Study for the Adjuvant Treatment of Breast Cancer
Studies on postoperative adjuvant albumin paclitaxel in domestic breast cancer patients are less reported, especially in large samples, and more studies focus more on the safety and tolerability of albumin paclitaxel use.
- Trial name
- NCT05420467
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- China
- Volunteers
- 2,413 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.